期刊文献+

NY-ESO-1抗原T细胞受体基因慢病毒载体的构建及鉴定

Construction and expression in Hela cell of NY-ESO-1 antigen T cell receptor lentiviral vector
下载PDF
导出
摘要 目的构建NY-ESO-1抗原T细胞受体基因(TCellReceptor,TCR)的慢病毒载体并获得重组慢病毒。方法设计特异性NY-ESO-1TCR的引物,用聚合酶链反应(PCR)对我们前期已克隆的NY-ESO-1TCRcDNA进行体外扩增,双酶切后定向插入到pCL20c-MSCV-GFP质粒,构建NY-ESO-1抗原特异性TCR基因的重组慢病毒载体pCL20c-MSCV-ESOTCR,并经酶切、PCR及测序鉴定。用pCL20c-MSCV-ESOTCR﹑pCL20c-HIV-gp、pCAG4-RTR2和CAG-VSV-G共转染T293包装细胞,获得上清,上清浓缩后感染Hela细胞,观察ESOTCR基因及蛋白水平的表达。结果经PCR及测序证实,成功构建重组慢病毒载体pCL20c-MSCV-ESOTCR,包装产毒后感染Hela细胞,RT-PCR法及荧光显微镜均能检测及观察到基因及蛋白水平的表达。结论成功构建了表达NY-ESO-1抗原T细胞受体基因(TCellReceptor,TCR)的重组慢病毒载体。 Objective To establish an NY-ESO-1(New York esophageal squamous cell carcinoma 1) T Cell receptor(TCR) recombinant lentiviral vector.Methods Specific NY-ESO-1 TCR primers were designed,and NY-ESO-1 TCR gene was amplified by PCR(polymerase chain reaction) with the template of NY-ESO-1 TCR cDNA,which we had cloned before in our lab.The PCR products were digested by EcoR I and Not I,and directly cloned into pCL20c-MSCV-GFP vector named pCL20c-MSCV-ESOTCR and confirmed by digestion,PCR and sequencing.pCL20c-MSCV-ESOTCR and other three package plasmids pCL20c-HIV-gp、pCAG4-RTR2 and CAG-VSV-G were co-infected into T293 cell.Hela cells were infected with above collected supernatants and ESOTCR gene and protein were detected.Results NY-ESO-1 TCR lentiviral vector was successfully constructed by PCR and sequenceing and packaged.Recombinant lentiviral ESOTCR gene was detected by PCR and protein observed under the flurescence microscope.Conclusion We successfully established a pCL20c-MSCV-ESOTCR lentiviral vector which could express NY-ESO-1 TCR gene and protein.
出处 《北京医学》 CAS 2010年第12期951-954,共4页 Beijing Medical Journal
基金 北京市自然科学基金(7092044) 留学人员科技活动项目择优资助(205)
关键词 NY-ESO-1T细胞受体 慢病毒载体 HELA细胞 NY-ESO-1 TCR lentiviral vector Hela cell
  • 相关文献

参考文献1

二级参考文献11

  • 1Ji-Yao Sun,David Senitzer,Stephen J. Forman,Saswati Chatterjee,K. K. Wong.Identification of new MHC-restriction elements for presentation of the p210BCR-ABL fusion region to human cytotoxic T lymphocytes[J].Cancer Immunology Immunotherapy.2003(12)
  • 2Bronte V,Apolloni E,Ronca R,et al.Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo[].Cancer Research.2000
  • 3Dudley ME,Rosenberg SA.Adoptive-cell-transfer therapy for the treatment of patients with cancer[].Nature Reviews Cancer.2003
  • 4Tsuji T,Yasukawa M,Matsuzaki J,et al.Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes[].Blood.2005
  • 5Warren EH,Gavin M,Greenberg PD,Riddell SR.Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation[].Current Opinion in Hematology.1998
  • 6Goulmy E.Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy[].Cancer Journal.2004
  • 7Haque T,Wilkie GM,Taylor C,et al.Treatment of Epstein- Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells[].The Lancet.2002
  • 8Klein C,Bueler H,Mulligan RC.Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines[].The Journal of Experimental Medicine.2000
  • 9Kessels HWHG,Wolkers MC,van den Boom MD,van der Valk MA,Schumacher TNM.Immunotherapy through TCR gene transfer[].Nature Immunology.2001
  • 10Marijt WA,Heemskerk MH,Kloosterboer FM,et al.Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia[].Proceedings of the National Academy of Sciences of the United States of America.2003

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部